Our vision is to provide an innovative, cost effective, and efficient way to identify new active chemical starting points to feed into early drug discovery programs.
The rise of antibiotic resistance or the increase in dementia related diseases are some examples of the need for new and better medicines. Despite significant effort and enormous amounts of money being spent by Pharmaceutical companies in finding new chemical starting points (so-called hits), the chances of those hits being developed into next generation drugs still remain low. Critically, the identification and quality of the hits are essential to feed into early drug discovery programs, and thus to deliver new and better medicines to the market.
A critical aspect of the hit identification process is the quality of the library and the screening method used in order to increase the chances of finding high-quality hits to progress. The chemical space spanned for potential “drug-like” molecules is astronomic, it has been estimated to be in the order to 1062 molecules. A structurally diverse and complex compound screening collection, designed to cover a broad area of the chemical space, is of outstanding importance to increase the chances of finding new and better hits outside the limited regions covered by conventional screening libraries.